gyrA mutations in Mycoplasma genitalium and their contribution to moxifloxacin failure: time for the next generation of resistance-guided therapy.

Gerald L MurrayErica L PlummerKaveesha BodiyabaduLenka A VodstrcilJose L HuamanJennifer A DanielewskiTeck Phui ChuaDorothy A MachalekSuzanne GarlandMichelle DoyleEmma L SweeneyDavid M WhileyCatriona S Bradshaw

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Compared to parC S83I SNP alone, M. genitalium infections with dual mutations affecting parC/gyrA had twice the likelihood of failing moxifloxacin. While AMR varies by region globally, these data indicate that gyrA should be considered as a target for future resistance assays in Australasia. We propose a strategy for the next generation of resistance-guided therapy incorporating parC and gyrA testing.

Keyphrases

high throughput
genome wide
stem cells
gene expression
machine learning
mesenchymal stem cells
high density
data analysis
replacement therapy